Dr. Joseph M. Tuscano, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Southern California Keck School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 272
Licensed in California since 1990, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of Southern California Keck School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license G69025 (first issued 1990; current) · CA license G069025 (first issued 1990; current) -
Specialist
CA license G069025 (first issued 1990; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of California Davis Medical Center Sacramento, CA
- Enloe Health Chico, CA
- Mercy Medical Center Redding Redding, CA
- Adventist Health and Rideout Marysville, CA
- Marshall Medical Center Placerville, CA
Medical groups
- Regents of the Univ of Ca (1,584 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 272
- Services billed
- 1,452
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 520 | 196 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 170 | 25 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 110 | 25 |
| Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 53 | 39 |
| New patient office or other outpatient visit, 60-74 minutes | 35 | 35 |
| Established patient office or other outpatient visit, 30-39 minutes | 31 | 27 |
| Telephone medical discussion with physician, 21-30 minutes | 30 | 22 |
| Established patient office or other outpatient visit, 20-29 minutes | 16 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 75 |
| Imbruvica (ibrutinib) | 38 |
| Acyclovir Other prescribers in Sacramento, CA | 29 |
| Ondansetron Hcl Other prescribers in Sacramento, CA | 24 |
| Posaconazole | 20 |
| Prochlorperazine Maleate Other prescribers in Sacramento, CA | 13 |
| Inrebic (fedratinib dihydrochloride) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $201 in total to this clinician.
| Janssen Biotech, Inc. | $122 |
|---|---|
| Acrotech Biopharma Inc. | $44.79 |
| Celgene Corporation | $34.34 |
| Food and Beverage | $201 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 7 companies. The companies reported $3,120,753 in research payments for these studies, mostly to the institutions running them.
- Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT04450173 - Hase 2 Study of Epcoritamab (Epco) Plus Physician's Choice of Platinum-Containing Chemotherapy PreAutologous Hematopoietic Cell Transplantation (AutoHCT) Followed by Post-AutoHCT Epco Consolidation/ Maintenance in Re…
Genmab U.S., Inc. - X16043: pic-d (MLN9708 or ixazomib) in combination with clarithromycin, pomalidomide and dexamethasone) in patients with double refractory multiple myeloma
Takeda Pharmaceuticals U.S.A., Inc. - IIT_TUSCANO_ADCT-402-1
Adc Therapeutics America, Inc. - A Phase 2 Study of Odronextamab in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Before and After Chimeric Antigen Receptor (CAR) T-Cell Therapy
Regeneron Pharmaceuticals, Inc. - PII Combination of GA101 Ibrutinib ABT GDC199 in pts with previously untreated Indolent Lymphoma
Genentech, Inc. - A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06091865 - A phase ii study of brentuximab vedotin plus bendamustine for relapsedrefractory follicular lymphoma
Pfizer Inc. - A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma
Takeda Pharmaceuticals U.S.A., Inc. · Completed · NCT01712490
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.